Inimmune

We’re proud to announce our participation in a pioneering European project led by the Medical University of Vienna to develop a next-generation #vaccine against #influenza. For the initiative, Inimmune will provide its proprietary intranasal vaccine adjuvant INI-4001, which has capability to enhance vaccine efficacy and provide broader and longer-lasting protection against seasonal influenza strains and strains with pandemic potential. The consortium has submitted its proposal to European Health and Digital Executive Agency (HaDEA) and is seeking to be selected under the European Commission’s #EU4Health program. Read more here: https://lnkd.in/eghaGUaC

Today, we honor and thank the brave men and women who have served our country. We recognize the courage, commitment and sacrifices of our #veterans and their families. Thank you for the invaluable contributions you’ve made to our communities. #VeteransDay #ThankYou

At Inimmune, our passionate and highly skilled team drives the development of next-generation #immunotherapies to address a wide range of diseases and disorders. We want to highlight the invaluable contributions of our Senior Scientist Konner Jackson, whose innovation, dedication, and commitment to making a meaningful impact continue to drive our mission forward. #EmployeeSpotlight #Teamwork

This week, our CEO David Burkhart is in Boston for the Wilson Sonsini Goodrich & Rosati #Biotech Summit! He’s connecting with industry leaders and joining discussions on the innovations, challenges, and #healthcare trends shaping the future of biotech. Learn more: https://lnkd.in/eHTrtPgB

We’re at #ESMO25! The Inimmune team has joined the #oncology community in Berlin to explore the groundbreaking research advancing #cancer care. Connect with us!

The Inimmune team is on the move! This week, we’re visiting Curia’s Glasgow, UK facility supporting the manufacture of a new batch of INI-2004, an intranasal allergen #immunotherapy for the treatment of allergic rhinitis (AR). This step is a key part of preparing for Phase 2 clinical studies. Collaboration, innovation, and precision manufacturing—together, we’re advancing the future of #immunotherapy.

We’re excited to share that our latest paper, “In silico Discovery and Mechanistic Profiling of STING Agonists,” is now available online in the European Journal of Medicinal Chemistry.   This work highlights how computational screening and mechanistic profiling can uncover novel small-molecule STING agonists with potential in #immunotherapy and #vaccine adjuvants. Read more: https://lnkd.in/eKMkCTTA A huge thank you to our partners and team for driving this research forward.

The Inimmune team is presenting at The World Vaccine Congress Europe in Amsterdam! Juhienah Khalaf, Ph.D., Director of Chemistry, will co-present with Dr. Peter Tygesen, Business Development Director at SPI Pharma, on October 15th. The joint presentation will highlight recent progress across our pipeline of immunomodulators and adjuvant platforms. Our leadership team will be featured in multiple sessions at #WVCEU. Learn more here: https://lnkd.in/emYEjxf #WorldVaccineCongress

October is #HealthLiteracyMonth, a time to recognize the importance of making health information accessible and #healthcare easier to navigate. From #cancer to #allergy to infectious disease, #healthliteracy can improve outcomes for all. Help us spread this important message: https://lnkd.in/gbRDJUu8

This month, we honor the courage of breast cancer patients, survivors, and families, and we reaffirm the urgent need for better treatment options in #breastcancer and beyond. At Inimmune, we’re advancing INI-4001, our first-in-class TLR7/8 agonist, now in a Phase I trial for patients with advanced solid tumors. By activating antigen-presenting cells and enhancing anti-tumor immune responses, INI-4001 is designed to synergize with anti-PD-1 therapy — a strategy with potential relevance for multiple cancers, including breast cancer. While progress in oncology comes step by step, we are inspired by the growing body of research demonstrating how innate immune activation can make checkpoint inhibitors more effective, and we are proud to be contributing to this movement with INI-4001. This #BreastCancerAwarenessMonth, we stand with the community, celebrate the progress being made, and remain committed to advancing bold new immunotherapies for patients in need. #BreastCancerAwareness